APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Complement Protein C5 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Complement Protein C5 Inhibitors Market Outlook and Growth Opportunities 2026

Report ID 173980180429 December 2025190 pages

Choose your research edition.

Industry ResearchComplement Protein C5 Inhibitors Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Complement Protein C5 Inhibitors Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Complement Protein C5 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Complement Protein C5 Inhibitors Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Complement Protein C5 Inhibitors Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Complement Protein C5 Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Complement Protein C5 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Complement Protein C5 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Complement Protein C5 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Complement Protein C5 Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Complement Protein C5 Inhibitors market include UCB, Alexion Pharmaceuticals, Astellas Pharma, Regeneron Pharmaceuticals, Amgen, Roche and Samsung Bioepis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Complement Protein C5 Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Complement Protein C5 Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Complement Protein C5 Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Complement Protein C5 Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Complement Protein C5 Inhibitors Segment by Company

UCB

Alexion Pharmaceuticals

Astellas Pharma

Regeneron Pharmaceuticals

Amgen

Roche

Samsung Bioepis

Complement Protein C5 Inhibitors Segment by Type

Subcutaneous Administration

Oral Administration

Intravenous Injection

Complement Protein C5 Inhibitors Segment by Application

Geographic Atrophy (GA)

Atypical Hemolytic Uremic Syndrome (aHUS)

Neuromyelitis Optica Spectrum Disorde (NMOSD)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Others

Complement Protein C5 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Complement Protein C5 Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Complement Protein C5 Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Complement Protein C5 Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze Complement Protein C5 Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Complement Protein C5 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Complement Protein C5 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Complement Protein C5 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Complement Protein C5 Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Complement Protein C5 Inhibitors industry.

Chapter 3: Detailed analysis of Complement Protein C5 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Complement Protein C5 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Complement Protein C5 Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Complement Protein C5 Inhibitors Industry Trends Table 2. Complement Protein C5 Inhibitors Industry Drivers Table 3. Complement Protein C5 Inhibitors Industry Opportunities and Challenges Table 4. Complement Protein C5 Inhibitors Industry Restraints Table 5. Global Complement Protein C5 Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Complement Protein C5 Inhibitors Revenue Share by Company (2021-2026) Table 7. Global Complement Protein C5 Inhibitors Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Complement Protein C5 Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global Complement Protein C5 Inhibitors Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Complement Protein C5 Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global Complement Protein C5 Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global Complement Protein C5 Inhibitors Company, Product Type & Application Table 13. Global Complement Protein C5 Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Complement Protein C5 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Subcutaneous Administration Table 18. Significant Companies of Oral Administration Table 19. Significant Companies of Intravenous Injection Table 20. Global Complement Protein C5 Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Complement Protein C5 Inhibitors Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Complement Protein C5 Inhibitors Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Complement Protein C5 Inhibitors Sales Volume Share by Type (2021-2026) Table 24. Global Complement Protein C5 Inhibitors Sales Volume Share by Type (2027-2032) Table 25. Global Complement Protein C5 Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Complement Protein C5 Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Complement Protein C5 Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Complement Protein C5 Inhibitors Sales Value Share by Type (2021-2026) Table 29. Global Complement Protein C5 Inhibitors Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Geographic Atrophy (GA) Table 31. Significant Companies of Atypical Hemolytic Uremic Syndrome (aHUS) Table 32. Significant Companies of Neuromyelitis Optica Spectrum Disorde (NMOSD) Table 33. Significant Companies of Paroxysmal Nocturnal Hemoglobinuria (PNH) Table 34. Significant Companies of Others Table 35. Global Complement Protein C5 Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Complement Protein C5 Inhibitors Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Complement Protein C5 Inhibitors Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Complement Protein C5 Inhibitors Sales Volume Share by Application (2021-2026) Table 39. Global Complement Protein C5 Inhibitors Sales Volume Share by Application (2027-2032) Table 40. Global Complement Protein C5 Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Complement Protein C5 Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Complement Protein C5 Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Complement Protein C5 Inhibitors Sales Value Share by Application (2021-2026) Table 44. Global Complement Protein C5 Inhibitors Sales Value Share by Application (2027-2032) Table 45. Global Complement Protein C5 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Complement Protein C5 Inhibitors Sales by Region (2021-2026) & (K Units) Table 47. Global Complement Protein C5 Inhibitors Sales Market Share by Region (2021-2026) Table 48. Global Complement Protein C5 Inhibitors Sales by Region (2027-2032) & (K Units) Table 49. Global Complement Protein C5 Inhibitors Sales Market Share by Region (2027-2032) Table 50. Global Complement Protein C5 Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Complement Protein C5 Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Complement Protein C5 Inhibitors Sales Value Share by Region (2021-2026) Table 53. Global Complement Protein C5 Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Complement Protein C5 Inhibitors Sales Value Share by Region (2027-2032) Table 55. Global Complement Protein C5 Inhibitors Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Complement Protein C5 Inhibitors Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Complement Protein C5 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Complement Protein C5 Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Complement Protein C5 Inhibitors Sales by Country (2021-2026) & (K Units) Table 60. Global Complement Protein C5 Inhibitors Sales Market Share by Country (2021-2026) Table 61. Global Complement Protein C5 Inhibitors Sales by Country (2027-2032) & (K Units) Table 62. Global Complement Protein C5 Inhibitors Sales Market Share by Country (2027-2032) Table 63. Global Complement Protein C5 Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Complement Protein C5 Inhibitors Sales Value Market Share by Country (2021-2026) Table 65. Global Complement Protein C5 Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Complement Protein C5 Inhibitors Sales Value Market Share by Country (2027-2032) Table 67. UCB Company Information Table 68. UCB Business Overview Table 69. UCB Complement Protein C5 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. UCB Complement Protein C5 Inhibitors Product Portfolio Table 71. UCB Recent Development Table 72. Alexion Pharmaceuticals Company Information Table 73. Alexion Pharmaceuticals Business Overview Table 74. Alexion Pharmaceuticals Complement Protein C5 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Alexion Pharmaceuticals Complement Protein C5 Inhibitors Product Portfolio Table 76. Alexion Pharmaceuticals Recent Development Table 77. Astellas Pharma Company Information Table 78. Astellas Pharma Business Overview Table 79. Astellas Pharma Complement Protein C5 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Astellas Pharma Complement Protein C5 Inhibitors Product Portfolio Table 81. Astellas Pharma Recent Development Table 82. Regeneron Pharmaceuticals Company Information Table 83. Regeneron Pharmaceuticals Business Overview Table 84. Regeneron Pharmaceuticals Complement Protein C5 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Regeneron Pharmaceuticals Complement Protein C5 Inhibitors Product Portfolio Table 86. Regeneron Pharmaceuticals Recent Development Table 87. Amgen Company Information Table 88. Amgen Business Overview Table 89. Amgen Complement Protein C5 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Amgen Complement Protein C5 Inhibitors Product Portfolio Table 91. Amgen Recent Development Table 92. Roche Company Information Table 93. Roche Business Overview Table 94. Roche Complement Protein C5 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Roche Complement Protein C5 Inhibitors Product Portfolio Table 96. Roche Recent Development Table 97. Samsung Bioepis Company Information Table 98. Samsung Bioepis Business Overview Table 99. Samsung Bioepis Complement Protein C5 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Samsung Bioepis Complement Protein C5 Inhibitors Product Portfolio Table 101. Samsung Bioepis Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Complement Protein C5 Inhibitors Distributors List Table 105. Complement Protein C5 Inhibitors Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Complement Protein C5 Inhibitors Product Image Figure 2. Global Complement Protein C5 Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Complement Protein C5 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global Complement Protein C5 Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global Complement Protein C5 Inhibitors Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Complement Protein C5 Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Subcutaneous Administration Image Figure 10. Oral Administration Image Figure 11. Intravenous Injection Image Figure 12. Global Complement Protein C5 Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Complement Protein C5 Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Complement Protein C5 Inhibitors Sales Volume Share by Type (2021-2032) Figure 15. Global Complement Protein C5 Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Complement Protein C5 Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Complement Protein C5 Inhibitors Sales Value Share by Type (2021-2032) Figure 18. Geographic Atrophy (GA) Image Figure 19. Atypical Hemolytic Uremic Syndrome (aHUS) Image Figure 20. Neuromyelitis Optica Spectrum Disorde (NMOSD) Image Figure 21. Paroxysmal Nocturnal Hemoglobinuria (PNH) Image Figure 22. Others Image Figure 23. Global Complement Protein C5 Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Complement Protein C5 Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Complement Protein C5 Inhibitors Sales Volume Share by Application (2021-2032) Figure 26. Global Complement Protein C5 Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Complement Protein C5 Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Complement Protein C5 Inhibitors Sales Value Share by Application (2021-2032) Figure 29. Global Complement Protein C5 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Complement Protein C5 Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Complement Protein C5 Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Complement Protein C5 Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Complement Protein C5 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 34. North America Complement Protein C5 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Complement Protein C5 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Complement Protein C5 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Complement Protein C5 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Complement Protein C5 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Complement Protein C5 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 40. South America Complement Protein C5 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Complement Protein C5 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Complement Protein C5 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Complement Protein C5 Inhibitors Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Complement Protein C5 Inhibitors Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Subcutaneous Administration
  • Oral Administration
  • Intravenous Injection
Applications
  • Geographic Atrophy (GA)
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Neuromyelitis Optica Spectrum Disorde (NMOSD)
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Others
Companies covered
  • UCB
  • Alexion Pharmaceuticals
  • Astellas Pharma
  • Regeneron Pharmaceuticals
  • Amgen
  • Roche
  • Samsung Bioepis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Complement Protein C5 Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global Complement Protein C5 Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global Complement Protein C5 Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Complement Protein C5 Inhibitors Market Dynamics
  1. 2.1 Complement Protein C5 Inhibitors Industry Trends
  2. 2.2 Complement Protein C5 Inhibitors Industry Drivers
  3. 2.3 Complement Protein C5 Inhibitors Industry Opportunities and Challenges
  4. 2.4 Complement Protein C5 Inhibitors Industry Restraints
3 Complement Protein C5 Inhibitors Market by Company
  1. 3.1 Global Complement Protein C5 Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global Complement Protein C5 Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global Complement Protein C5 Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global Complement Protein C5 Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global Complement Protein C5 Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global Complement Protein C5 Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global Complement Protein C5 Inhibitors Company Product Type and Application
  8. 3.8 Global Complement Protein C5 Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Complement Protein C5 Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Complement Protein C5 Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Complement Protein C5 Inhibitors Market by Type
  1. 4.1 Complement Protein C5 Inhibitors Type Introduction
  2. 4.1.1 Subcutaneous Administration
  3. 4.1.2 Oral Administration
  4. 4.1.3 Intravenous Injection
  5. 4.2 Global Complement Protein C5 Inhibitors Sales Volume by Type
  6. 4.2.1 Global Complement Protein C5 Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Complement Protein C5 Inhibitors Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Complement Protein C5 Inhibitors Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Complement Protein C5 Inhibitors Sales Value by Type
  10. 4.3.1 Global Complement Protein C5 Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Complement Protein C5 Inhibitors Sales Value by Type (2021-2032)
  12. 4.3.3 Global Complement Protein C5 Inhibitors Sales Value Share by Type (2021-2032)
5 Complement Protein C5 Inhibitors Market by Application
  1. 5.1 Complement Protein C5 Inhibitors Application Introduction
  2. 5.1.1 Geographic Atrophy (GA)
  3. 5.1.2 Atypical Hemolytic Uremic Syndrome (aHUS)
  4. 5.1.3 Neuromyelitis Optica Spectrum Disorde (NMOSD)
  5. 5.1.4 Paroxysmal Nocturnal Hemoglobinuria (PNH)
  6. 5.1.5 Others
  7. 5.2 Global Complement Protein C5 Inhibitors Sales Volume by Application
  8. 5.2.1 Global Complement Protein C5 Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Complement Protein C5 Inhibitors Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Complement Protein C5 Inhibitors Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Complement Protein C5 Inhibitors Sales Value by Application
  12. 5.3.1 Global Complement Protein C5 Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Complement Protein C5 Inhibitors Sales Value by Application (2021-2032)
  14. 5.3.3 Global Complement Protein C5 Inhibitors Sales Value Share by Application (2021-2032)
6 Complement Protein C5 Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global Complement Protein C5 Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Complement Protein C5 Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Complement Protein C5 Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global Complement Protein C5 Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global Complement Protein C5 Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Complement Protein C5 Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global Complement Protein C5 Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global Complement Protein C5 Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global Complement Protein C5 Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Complement Protein C5 Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America Complement Protein C5 Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Complement Protein C5 Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe Complement Protein C5 Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Complement Protein C5 Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Complement Protein C5 Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Complement Protein C5 Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America Complement Protein C5 Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Complement Protein C5 Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Complement Protein C5 Inhibitors Sales Value Share by Country, 2025 VS 2032
7 Complement Protein C5 Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global Complement Protein C5 Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Complement Protein C5 Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Complement Protein C5 Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global Complement Protein C5 Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global Complement Protein C5 Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global Complement Protein C5 Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global Complement Protein C5 Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global Complement Protein C5 Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Complement Protein C5 Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Complement Protein C5 Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Complement Protein C5 Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 UCB
  2. 8.1.1 UCB Company Information
  3. 8.1.2 UCB Business Overview
  4. 8.1.3 UCB Complement Protein C5 Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 UCB Complement Protein C5 Inhibitors Product Portfolio
  6. 8.1.5 UCB Recent Developments
  7. 8.2 Alexion Pharmaceuticals
  8. 8.2.1 Alexion Pharmaceuticals Company Information
  9. 8.2.2 Alexion Pharmaceuticals Business Overview
  10. 8.2.3 Alexion Pharmaceuticals Complement Protein C5 Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Alexion Pharmaceuticals Complement Protein C5 Inhibitors Product Portfolio
  12. 8.2.5 Alexion Pharmaceuticals Recent Developments
  13. 8.3 Astellas Pharma
  14. 8.3.1 Astellas Pharma Company Information
  15. 8.3.2 Astellas Pharma Business Overview
  16. 8.3.3 Astellas Pharma Complement Protein C5 Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Astellas Pharma Complement Protein C5 Inhibitors Product Portfolio
  18. 8.3.5 Astellas Pharma Recent Developments
  19. 8.4 Regeneron Pharmaceuticals
  20. 8.4.1 Regeneron Pharmaceuticals Company Information
  21. 8.4.2 Regeneron Pharmaceuticals Business Overview
  22. 8.4.3 Regeneron Pharmaceuticals Complement Protein C5 Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Regeneron Pharmaceuticals Complement Protein C5 Inhibitors Product Portfolio
  24. 8.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 8.5 Amgen
  26. 8.5.1 Amgen Company Information
  27. 8.5.2 Amgen Business Overview
  28. 8.5.3 Amgen Complement Protein C5 Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Amgen Complement Protein C5 Inhibitors Product Portfolio
  30. 8.5.5 Amgen Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Complement Protein C5 Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Roche Complement Protein C5 Inhibitors Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Samsung Bioepis
  38. 8.7.1 Samsung Bioepis Company Information
  39. 8.7.2 Samsung Bioepis Business Overview
  40. 8.7.3 Samsung Bioepis Complement Protein C5 Inhibitors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Samsung Bioepis Complement Protein C5 Inhibitors Product Portfolio
  42. 8.7.5 Samsung Bioepis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Complement Protein C5 Inhibitors Value Chain Analysis
  2. 9.1.1 Complement Protein C5 Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Complement Protein C5 Inhibitors Sales Mode & Process
  6. 9.2 Complement Protein C5 Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Complement Protein C5 Inhibitors Distributors
  9. 9.2.3 Complement Protein C5 Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst